Yoshio Kurihara Selected Research

Yoshio Kurihara Research Topics

Disease

25	Type 2 Diabetes Mellitus (MODY) 05/2024 - 01/2015
6	Body Weight (Weight, Body) 12/2023 - 02/2018
4	Hypoglycemia (Reactive Hypoglycemia) 05/2022 - 03/2019
3	Chronic Renal Insufficiency 11/2022 - 11/2019
3	Albuminuria 11/2022 - 07/2017
3	Hyperglycemia 08/2021 - 01/2015
3	Atherosclerosis 10/2017 - 01/2015
2	Fatty Liver 05/2024 - 07/2021
2	Insulin Resistance 05/2024 - 12/2023
2	Non-alcoholic Fatty Liver Disease 04/2022 - 07/2021
2	Diabetes Mellitus 01/2022 - 08/2021
2	Obesity 01/2022 - 09/2021
2	Hypertension (High Blood Pressure) 10/2021 - 01/2020
1	Hypertriglyceridemia 10/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2022
1	Hepatitis 04/2022
1	Fibrosis (Cirrhosis) 04/2022
1	Weight Loss (Weight Reduction) 07/2021
1	Ketosis 02/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 11/2019
1	Body Weight Changes 01/2018

Drug/Important Bio-Agent (IBA)

9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2016
5	semaglutideIBA 05/2024 - 03/2021
5	LipidsIBA 12/2023 - 01/2016
5	Dipeptidyl-Peptidase IV InhibitorsIBA 10/2021 - 01/2016
4	Liraglutide FDA Link 01/2023 - 01/2015
4	dulaglutideIBA 01/2023 - 05/2019
4	Insulin (Novolin)FDA Link 05/2022 - 01/2018
4	Blood Glucose (Blood Sugar)IBA 01/2022 - 01/2016
4	SodiumIBA 08/2021 - 01/2019
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2021 - 01/2018
3	Metformin (Glucophage)FDA LinkGeneric 05/2024 - 01/2016
3	Glucagon-Like Peptide-1 ReceptorIBA 11/2022 - 05/2019
3	Sodium-Glucose Transport ProteinsIBA 05/2022 - 01/2020
2	Semaphorins (Semaphorin)IBA 01/2023 - 03/2021
2	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2022 - 01/2020
2	AlbuminsIBA 11/2022 - 03/2019
2	Glucagon-Like Peptide 1 (GLP 1)IBA 11/2022 - 01/2015
2	IncretinsIBA 01/2022 - 01/2016
2	Antihypertensive Agents (Antihypertensives)IBA 10/2021 - 07/2017
2	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 10/2021 - 01/2020
2	CanagliflozinIBA 08/2021 - 01/2020
2	3- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA 08/2021 - 01/2020
2	dapagliflozinIBA 07/2021 - 01/2019
2	Pioglitazone (Actos)FDA Link 07/2021 - 01/2019
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 03/2021 - 05/2019
1	EnzymesIBA 12/2023
1	Hemoglobins (Hemoglobin)IBA 11/2022
1	CreatinineIBA 11/2022
1	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 10/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2022
1	Fibric Acids (Fibrates)IBA 10/2022
1	Collagen Type IV (Type IV Collagen)IBA 04/2022
1	Alanine Transaminase (SGPT)IBA 04/2022
1	IronIBA 01/2022
1	Dietary IronIBA 01/2022
1	ORALIT (ORS)IBA 09/2021
1	Triglycerides (Triacylglycerol)IBA 07/2021
1	ThiazolidinesIBA 07/2021
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 07/2021
1	Hypoglycemic Agents (Hypoglycemics)IBA 03/2021
1	Glucagon-Like Peptides (Enteroglucagon)IBA 03/2021
1	Ketone BodiesIBA 02/2021
1	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 01/2020
1	insulin aspart drug combination insulin degludecIBA 01/2020
1	ipragliflozinIBA 03/2019
1	repaglinide (Prandin)FDA Link 03/2019
1	trelagliptinIBA 02/2018
1	lixisenatideIBA 01/2018
1	VildagliptinIBA 10/2017
1	AdipokinesIBA 10/2017
1	glimepiride (Amarel)FDA LinkGeneric 01/2016
1	Sitagliptin Phosphate (Januvia)FDA Link 01/2016

Therapy/Procedure

9	Therapeutics 10/2022 - 01/2015
8	Glycemic Control 05/2022 - 01/2018